Abstract
The development of tolerance to the cataleptic effect of the selective D-1 antagonist SCH 23390 (0.5 mg/kg/day SC or 0.1 mg/kg/day SC) and haloperidol (1 mg/kg/day SC) during repeated administration was investigated. Catalepsy in rats was measured using the horizontal bar method. SCH 23390 induced a dose-related cataleptic effect of short duration, whereas the cataleptic effect of haloperidol appeared more slowly and lasted longer.
Marked tolerance to the cataleptic effect of haloperidol developed already 6 days from the beginning of the treatment. The cataleptic effect of the higher dose regimen of SCH 23390 was also significantly reduced after 6 days' treatment. However, unlike haloperidol, this subacute tolerance was gradually reversed and was no longer significant after 12 and 18 days. The cataleptic response to the lower dose of SCH 23390 (0.1 mg/kg/day) was not significantly altered during the treatment and no initial catalepsy tolerance was observed with this dose regimen. These results suggest that different mechanisms are involved in the expression of cataleptic behaviour during chronic treatment with SCH 23390 and classical antipsychotics, such as haloperidol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersen PH (1988) Comparison of the pharmacological characteristics of (3H)raclopride and (3H)SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146:113–120
Arnt J (1985) Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine pretreated but not in normal rats. Eur J Pharmacol 113:79–88
Bischoff S, heinrich M, Sonntag JM, Krauss J (1986) The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors. Eur J Pharmacol 129:367–370
Campbell A, Baldessarini R (1981) Tolerance to behavioral effects of haloperidol. Life Sci 29:1341–1346
Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with classical neuroleptics. Life Sci 34:1529–1540
Creese I, Chen A (1985) Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. Eur J Pharmacol 109:127–128
Ezrin-Waters C, Seeman P (1977) Tolerance to haloperidol catalepsy. Eur J Pharmacol 41:321–327
de Graaf CJ, Korf J (1986) Conditional tolerance to haloperidol induced catalepsy is not caused by striatal dopamine receptor supersensitivity. Psychopharmacology 90:54–57
Hess EJ, Albers LJ, Hoang L, Creese I (1986) Effects of chronic treatment on the biochemical and behavioral properties of D-1 and D-2 dopamine receptors: potentiated behavioral responses to D-2 dopamine agonist after selective D-1 receptor upregulation. J Pharmacol Exp Ther 238:846–854
Hess EJ, Norman AB, Creese I (1988) Chronic treatment with dopamine receptor antagonists: behavioral and pharmacological effects on D-1 and D-2 dopamine receptors. J Neurosci 8:2361–2370
Hicks PE, Schoemacher H, Langer SZ (1984) 5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain. Eur J Pharmacol 91:153–154
Iorio LC, Barnett A, Leitz FG, Houser VP, Korduba CA (1983) SCH 23390 a potential benzazepine antipsychotic with unique interactions on dopaminergic system. J Pharmacol Exp Ther 226:462–468
Kilts CD, Dew KL, Ely TD, Mailman R (1985) Quantification of R-(+)-7-chloro-8-hydroxyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-methyl-3-benzazepine in brain and blood by use of reversedphase high-performance liquid chromatography with electrochemical detection. J Chromatogr 342:452–457
Koulu M, Lappalainen J, Pesonen UM, Hietala J, Syvälahti E (1988) Chronic treatment with SCH 23390, a selective D-1 blocker, decreases dopamine metabolism in rat caudate nucleus. Eur J Pharmacol 155:313–316
Mailman RB, Schultz DW, Lewis MH, Staples L, Rollema H, Dehaven DL (1984) SCH-23390: a selective D-1 dopamine antagonist with potent D-2 behavioral actions. Eur J Pharmacol 101:159–160
Meller E, Kuga S, Friedhoff AJ, Goldstein M (1985) Selective D-2 receptor agonist prevent catalepsy induced by SCH 23390, a selective D-1 receptor antagonist. Life Sci 36:1857–1864
Morelli M, Di Chiara C (1985) Catalepsy induced by SCH 23390 in rats. Eur J Pharmacol 117:179–185
Nicklaus K, McGonigle P, Molinoff PB (1988) 3H-SCH 23390 labels both dopamine-1 and 5-hydroxytryptamine-1c receptors in the choroid plexus. J Pharmacol Exp Ther 247:343–348
Nielsen EB, Jepsen SA (1985) Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur J Pharmacol 111:167–176
Ögren S-O, Fuxe K (1988) D-1 and D-2 receptor antagonist induce catalepsy via different efferent striatal pathways. Neurosci Lett 85:333–338
Poulos CX, Hinson R (1982) Pavlovian conditional tolerance to haloperidol catalepsy: evidence of dynamic adaptation in the dopaminergic system. Science 218:491–492
Schultz WS, Staples L, Mailman R (1985) SCH 233990 causes persistent antidopaminergic effects in vivo: evidence for longterm occupation of receptors. Life Sci 36:1941–1948
Undie AS, Friedman E (1988) Differences in the cataleptogenic actions of SCH 23390 and selected classical neuroleptics. Psychopharmacology 96:311–316
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lappalainen, J., Hietala, J. & Syvälahti, E. Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration. Psychopharmacology 98, 472–475 (1989). https://doi.org/10.1007/BF00441944
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00441944